Measles

Lore & Background

Symptoms of measles typically develop 10–12 days after exposure and last 7–10 days. Small white spots known as Koplik spots may appear inside the mouth 1–2 days before the rash. A red, flat rash usually starts on the face and spreads to the rest of the body three to five days after symptoms begin. Common complications include diarrhea (8% of cases), middle ear infection (7%), and pneumonia (6%), partly due to measles-induced immunosuppression. Less common complications include seizures, blindness, or inflammation of the brain.

Reader's Guide

Measles remains one of the leading vaccine-preventable causes of death, affecting about 10 million people annually, primarily in developing areas of Africa and Asia. However, rates of disease and deaths have increased from 2017 onward due to decreased vaccination. The measles vaccine is safe and very effective, often delivered in combination with other vaccines; more than 95% of a community must be vaccinated to achieve herd immunity. The virus causes 'immune amnesia,' depleting previously acquired immune memory for up to three years, increasing susceptibility to other infections. Measles is not known to occur in other animals.

Did You Know?

• Measles is so contagious that nine out of ten non-immune people sharing living space with an infected person will become infected.
• The measles virus can cause 'immune amnesia,' destroying memory lymphocytes and weakening immunity to other diseases for up to three years.
• In parts of Africa, the case fatality rate for measles can be high in refugee settlements, though exact figures vary widely depending on context and healthcare access.

The Contagion Engine: Transmission and the Symptom Arc

Measles is an airborne illness that moves through communities with extraordinary efficiency. An infected person's coughs and sneezes release the virus into the air, and direct contact with mouth or nasal secretions offers another route. The spread is nearly relentless: nine out of ten susceptible people sharing a living space with a sick individual will become infected. Crucially, a person is contagious from four days before the rash appears through four days after, so the virus circulates before anyone notices illness. Symptoms typically emerge ten to twelve days after exposure and last roughly seven to ten days. The opening phase resembles a common cold—fever that can exceed 40 °C, a cough, a runny nose, and inflamed eyes. Two or three days in, small white Koplik spots may appear inside the mouth. Three to five days after the first symptoms, a flat red rash breaks out on the face and behind the ears, then marches across the body. Measles is not known to infect any animal besides humans, and most survivors do not catch it a second time.

The Immune Toll: Complications and Vulnerable Populations

About 30% of measles cases develop complications, making the disease far more dangerous than its cold-like opening suggests. The virus damages the membranes lining the nose, throat, and lungs, opening the door to secondary bacterial pneumonia and bronchitis. It can erode the Eustachian tube lining, inviting middle-ear infections, and its intestinal invasion produces diarrhea that in severe cases leads to dehydration. In rare cases the virus invades the brain, triggering encephalitis. The broader immune suppression caused by measles plays a role. A mechanism called "immune amnesia" involves the virus targeting memory cells, with longer-term consequences for the body's defenses. Pregnant women face heightened risks: greater likelihood of hospitalization, pneumonia, and death, along with increased chances of miscarriage, premature delivery, and low birth weight. In the United States, the CDC estimates one in five unvaccinated people who contract measles will require hospitalization, and between one and three per thousand children will die. In parts of Africa, case fatality rates reach 6% in settled populations and as high as 30% in refugee settlements. Pneumonia and encephalitis are the leading killers. Immunocompromised patients present a diagnostic challenge because the rash and conjunctivitis that normally signal infection depend on a functioning immune system.

No Cure, Only Care: Managing an Active Infection

Once measles takes hold, medicine offers no specific antiviral treatment. Management is entirely supportive: keeping the patient hydrated with slightly sweet and salty oral rehydration fluids, encouraging healthy food, and using medications to bring down the fever. If secondary bacterial infections take root—middle-ear infections appear in about 7% of cases, pneumonia in about 6%—antibiotics become necessary. For children under five, vitamin A supplementation is recommended as part of the care protocol. The mortality stakes vary dramatically by context. Among U.S. In settings where malnutrition is widespread, that figure can climb to 10%. The youngest children bear the heaviest burden: most measles deaths occur in those under five years old. Testing suspected cases for the measles virus is not merely a clinical step but a public health imperative, enabling contact tracing and community response. Because the virus is contagious from four days before the rash through four days after, early identification is critical to stopping further transmission. The disease, while often stereotyped as a childhood illness, can strike anyone of any age who lacks immunity.

The Long Arc: Global Mortality and the Vaccination Story

Measles has been one of the leading vaccine-preventable causes of death worldwide, and the numbers tell a story of both tragedy and triumph. In 1980, an estimated 2.6 million people died from the disease. The vaccine itself is safe and highly effective, often delivered in combination with other vaccines. Because measles spreads so readily through communities, achieving herd immunity requires more than 95% of the population to be vaccinated. The disease still affects about 10 million people annually, concentrated in the developing regions of Africa and Asia. Yet the trajectory has reversed. From 2017 onward, rates of infection and death have climbed again, driven by declining vaccination coverage. The story of measles is thus not a finished chapter but an ongoing negotiation between public health infrastructure and community trust.